IPH2101, also known as anti-KIR1-7F9 monoclonal antibody (mAb; lirilumab is a recombinant version of this mAb), blocks common inhibitory KIRs (KIR2DL/DS-1, -2, and -3), which bind to HLA-C alleles and augment NK cell-mediated killing in HLA-C-expressing leukemia cells [60]. The gene discussed is HLA-C; the disease is leukemia.